Introduction/Overview
Calceolarioside B (CAS number: 105471-98-5) is a natural phenylethanoid glycoside compound originally isolated from the leaves of Akebia quinata, a plant in the genus Calceolarioside. As a naturally occurring product with a unique structure, lignin B has attracted widespread attention due to its diverse biological activities, especially in the fields of anti-inflammatory, immune regulation, antiviral, and anticancer effects, demonstrating significant potential. In recent years, with the in-depth study of its pharmacological mechanism of action, the application value of lignan B in various disease models has gradually emerged, especially in the treatment research of malignant tumors such as liver cancer and prostate cancer, showing good prospects.
This review aims to systematically summarize the chemical structure and physicochemical properties, plant sources and extraction methods, pharmacological activity and mechanism of action of Mutong phenylethanolic glycoside B. Combined with its pharmacological parameters, it explores its clinical application potential and future research directions, providing theoretical basis and reference for natural product pharmacology and new drug development.
Chemical structure and physicochemical properties
Mutong phenylethanoid glycoside B belongs to the phenylethanoid glycoside class of natural products, with a molecular formula of C21H26O13 and a molecular weight of 494.45. The structure of this compound contains a phenylethanol core skeleton, which connects multiple hydroxyl and sugar groups, endowing it with high polarity and abundant hydrogen bonding ability. Its physical and chemical properties are manifested as:
- molecular weight：494.4500
- LogP-2.5, indicating its strong hydrophilicity and low fat solubility
- Topological Polar Surface Area (TPSA)194.25 Å ² indicates that the molecule has high polarity and potential hydrogen bond acceptor ability
- Number of hydrogen bond acceptors 11. Support its stable hydrogen bonding interaction with protein targets
- Blood-brain barrier permeability Low, indicating difficulty in penetrating the central nervous system barrier
- safety indicator No hepatotoxicity, cardiotoxicity, or hERG channel inhibition, Ames test negative, indicating good safety potential
The structural characteristics of Mutong phenylethanolic glycoside B endow it with strong affinity when interacting with biomolecules, particularly exhibiting significant biological activity in regulating enzyme activity and signal transduction pathways.
Plant sources and extraction methods
The main source of phenylethanolic acid B in Mutong is Akebia quinata, a traditional Chinese medicinal herb widely distributed in East Asia. The leaves of Akebia quinata are the main extraction site of this compound. During the extraction process, the following steps are usually taken:
- Ingredient Preparation Collect dry Akebia quinata leaves and crush them into fine powder.
- Solvent extraction Reflux extraction is carried out using methanol or ethanol as solvents, and the extraction time is generally several hours to ensure sufficient dissolution of the active ingredients.
- Crude extract concentration The extract is concentrated under reduced pressure to obtain a concentrated extract.
- Separation and purification Using column chromatography techniques (such as silica gel column, reverse phase C18 column) combined with high performance liquid chromatography (HPLC) for separation and purification, high-purity Mutong phenylethanolic acid B was finally obtained.
- Structural Identification Confirm the structure of the compound through methods such as nuclear magnetic resonance (NMR), mass spectrometry (MS), and infrared spectroscopy (IR).
In recent years, new technologies such as ultrasound assisted extraction and microwave-assisted extraction have also been applied to the extraction of phenylethanolic acid B from Houttuynia cordata, significantly improving the extraction efficiency and purity, and promoting the possibility of its large-scale preparation.
Pharmacological activity research
Mutong phenylethanolic glycoside B has shown a wide range of pharmacological effects in various biological activity studies, mainly including the following aspects:
1. Anti diabetes related enzyme activity
Mutong phenylethanolic glycoside B has been found to effectively inhibit the activity of aldose reductase (RLAR), with an IC50 value of 23.99 μ M. RLAR plays a key role in the occurrence and development of diabetes complications, especially diabetes retinopathy and neuropathy. By inhibiting RLAR, Akebia Akebiae Phenylethanoside B is expected to slow down tissue damage related to diabetes, and has potential value in prevention and treatment of diabetes complications.
2. Antiviral activity
Studies have shown that Akebia xylostenside B can inhibit the entry of COVID-19 Omicron mutant BA.2 into host cells, suggesting that Akebia xylostenside B has the potential to block virus infection. This discovery provides a new idea for the development of natural antiviral drugs against COVID-19 and its variants.
3. Anti inflammatory and immune regulatory effects
Mutong phenylethanolic glycoside B significantly reduces the level of pro-inflammatory cytokine IL-6, indicating its anti-inflammatory activity. IL-6, as a key regulatory factor in various inflammatory diseases and tumor microenvironments, its inhibition helps alleviate chronic inflammation and regulate immune responses. In addition, Mutong phenylethanolic acid B exhibits immunomodulatory activity, which can regulate immune cell function and enhance the body's immune defense ability.
4. Anti cancer activity
Mutong phenylethanolic glycoside B exhibits significant inhibitory effects on human hormone independent prostate cancer cells, demonstrating its potential anti-cancer activity. Based on molecular target analysis, it is possible that MuTong phenylethanolic acid B exerts anti-tumor effects by regulating multiple signaling pathways, especially in liver cancer related targets, which deserves further exploration.
Mechanism of action and molecular targets
The multiple pharmacological effects of Mutong phenylethanolic glycoside B are attributed to its interactions with various key molecular targets, especially in the mechanism of action of malignant tumors such as liver cancer, which has been extensively studied. The relevant targets include:
- BCL2 Anti apoptotic protein, regulates the process of cell apoptosis, and Mutong phenylethanolic acid B may promote tumor cell apoptosis by regulating BCL2 expression.
- STAT3 Signal transducer and activator of transcription factor 3, involved in cell proliferation, survival, and immune regulation, can inhibit the STAT3 signaling pathway and slow down tumor growth.
- TOP1 Topoisomerase I, involved in DNA replication and transcription, inhibits TOP1 and helps block tumor cell proliferation.
- TERT Telomerase reverse transcriptase maintains telomere length and promotes infinite cell proliferation. Xylenol B may inhibit TERT activity and limit the lifespan of tumor cells.
- PIK3CA The PI3K catalytic subunit participates in cell proliferation and survival signaling, and inhibiting PIK3CA helps prevent tumor progression.
- MMP9 Matrix metalloproteinase 9 promotes tumor cell invasion and metastasis, while lignan B can downregulate MMP9 expression and inhibit tumor metastasis.
- EGFR The epidermal growth factor receptor regulates cell proliferation and differentiation, and inhibiting the EGFR signaling pathway contributes to anti-tumor effects.
- TP53 Tumor suppressor protein regulates cell cycle and apoptosis, and lignan B may enhance cell self repair and apoptosis by activating TP53.
- NFKB1 Nuclear factor kappa B regulates inflammation and immune responses, and inhibiting NFKB1 helps alleviate inflammation and tumor microenvironment.
- AKT1 Protein kinase B is involved in cell metabolism and survival signaling, and inhibiting the AKT1 signaling pathway helps induce tumor cell apoptosis.
In summary, Mutong phenylethanolic acid B exhibits complex and effective pharmacological mechanisms by synergistically regulating cell proliferation, apoptosis, inflammation, and immune response through multiple targets and pathways.
Evaluation of drug properties and pharmacokinetics
The pharmacological parameters of Mutong phenylethanolic glycoside B indicate that it has good safety and potential drug development value. The specific evaluation is as follows:
- safety No hepatotoxicity, cardiotoxicity, or hERG channel inhibition, Ames test negative, indicating low genetic toxicity and cardiovascular risk.
- Pharmacokinetic characteristics LogP is -2.5, indicating strong hydrophilicity, which may affect oral bioavailability and cell membrane penetration ability. The high TPSA (194.25) and hydrogen bond receptor count (11) further support this viewpoint, which may limit its oral absorption and blood-brain barrier penetration.
- Blood-brain barrier permeability Low, which means that Mutong phenylethanolic acid B is not easily able to enter the central nervous system, making it suitable for targeting peripheral diseases and reducing central nervous system side effects.
- Metabolic stability At present, there is a lack of relevant metabolic kinetic data, and further research is needed on its in vivo metabolic pathways and half-life in the future.
Overall, Mutong phenylethanolic acid B is suitable for development as a peripheral acting drug, especially in the fields of anti-inflammatory, anti-tumor, and antiviral effects. Its high hydrophilicity and polarity suggest the need for drug formulation optimization or structural modification to enhance oral absorption and in vivo stability.
Clinical application prospects and prospects
Due to its multi-target and multifunctional pharmacological activities, Mutong phenylethanolic acid B has demonstrated broad clinical application potential
-
Antitumor therapy This provides a theoretical basis for the anticancer activity of liver cancer and hormone independent prostate cancer as adjuvant therapy or the development of new anti-tumor drugs. In the future, nanocarriers and targeted delivery technologies can be combined to enhance its efficacy and targeting.
-
Anti inflammatory and immune regulation By regulating IL-6 and immune cell function, Mutong phenylethanolic acid B is expected to be applied in the treatment of chronic inflammation, autoimmune diseases, and immune related diseases.
-
Development of antiviral drugs: It can inhibit the ability of COVID-19 Omicron BA. 2 mutant to invade host cells, providing a new direction for its research and development of antiviral drugs, especially in response to viral mutations and emerging infectious diseases.
-
Prevention and treatment of complications of diabetes By inhibiting RLAR activity, Akebia Phenylethanoside B may slow down the progression of diabetes retinopathy and neuropathy, and expand its application in metabolic diseases.
Future research should focus on:
- Pharmacokinetic characteristics and in vivo metabolic mechanism of phenylethanolic acid B in Mutong
- Structural optimization and derivative design to enhance bioavailability and targeting
- Safety and efficacy evaluation in preclinical animal models
- Combination therapy strategy and its synergistic effect in multiple pathological states
Conclusion
Mutong phenylethanolic glycoside B, as a natural phenylethanolic glycoside derived from Akebia quinata, has shown broad application prospects in anti-tumor, anti-inflammatory, immune regulation, and antiviral fields due to its unique chemical structure and rich biological activity. Its multi-target mechanism of action provides an important perspective for a deeper understanding of the pharmacological effects of natural products. Although research on its pharmacokinetics and clinical applications is still in its early stages, its good safety and multifunctional activity make it a strong candidate for natural drug development. In the future, through structural optimization and drug formulation innovation, Mutong phenylethanolic acid B is expected to become a new generation of natural product drugs, providing new solutions for the treatment of various diseases.
